Nemysis Limited Establishes Italian Subsidiary

DUBLIN, May 22, 2020 –​​Nemysis Limited, the Dublin-based pharmaceutical and healthcare company, announced that it opened the Italian subsidiary Nemysis S.r.l.

Currently, Nemysis has three high-potential products in its development pipeline and, preparing to the market presence is the next crucial step in the expansion strategy of the company.

​Danilo Casadei-Massari, Chairman and CEO of Nemsysis Ltd, believes that Italy can serve as a launchpad for future developments in Europe: “I am delighted that Nemysis has a continental Europe subsidiary now. Nemysis is looking forward to working in Italy as the well – established clinical expertise in the country adds important value to our R&D efforts and specifically our expeditious development of E40.”

Heading the Italian office will be Marco Cartolari – CEO of Nemysis S.r.l.- who, through his experience as CEO of Scharper Pharmaceuticals S.p.A., pioneered the nutraceutical market in Italy. Marco has deep expertise in bringing this class of products from the research stage into the market.

An integral part of Nemysis’ strategy is to cultivate and grow the company’s relationship with the Italian scientific community. According to Cartolari, “Italy represents one of the most developed food supplement markets, and the medical community is particularly open to the use of non-drug products to help patients, but only if backed by highly scientific validation. Our novel food products will fit this approach and establish new standards of quality in the nutraceutical market.”

Given the depth of experience in the Italian market by Nemysis’ management team, as well as the strong growth rates of the nutraceutical products market, Italy represents a unique opportunity for Nemysis’ commercial strategy.

About Nemysis:

Nemysis Ltd, a healthcare and pharmaceutical company, is focused on nutritional and pharmaceutical solutions which can protect against some of the negative consequences of nutrient deficiency, nutrient intolerances and sensitivities, paying particular attention to the need to safeguard the human microbiome.

  • Nemysis’s novel nanoparticulate iron is the first natural ferritin mimic, which can correct human iron deficiency and anemia, without negatively impacting the gut microbiome. Safety and efficacy have been demonstrated in controlled-repeat-dose [clinical] trials.
  • Nemysis’s novel E40 endopeptidase is gastric, trypsin and chymotrypsin resistant. It has been shown to destroy all the immuno-stimulatory epitopes of gluten, quenching the exacerbated inflammatory response of primed, gluten-sensitive and hyper-responsive human T cells. It is, therefore, suitable for the enzymatic management of gluten intolerance and sensitivity.

·         Nemysis has three further products in its pipeline for use in Iron Deficiency/Anaemia, Gluten sensitivity and Celiac Disease

Find out more   www.nemysisltd.com

Release date: May 22, 2020

Contact information

Danilo Casadei -Massari

Chairman of the Board

Nemysis Ltd

7 D’Olier Street

D02HF60 Dublin

Ireland

+35315313450

casadei-massari@nemysisltd.com

Nemysis Ltd Strengthens Its Management Team With Senior Regulatory Expert Estrella Bengio

Nemysis Limited today announced that it appointed Estrella Bengio as Global Regulatory Affairs Head.

Nemysis Limited today announced that it appointed Estrella Bengio as Global Regulatory Affairs Head.  Estrella brings with her over 30 years of senior leadership experience and expertise in Regulatory Affairs in Healthcare and Pharmaceuticals. She is highly qualified in navigating the regulatory process to bring effectively and rapidly innovative products to market.

She has served as Regulatory Affairs Director at Abbott Nutrition, covering a broad range of countries. She was a member of the Board of SNE (Specialized Nutrition Europe) covering Food Special Medical Purposes and Public Affairs and has also successfully covered leading positions in the regulatory area in Medical Nutritional International Industry (MNI). Before that, she covered the Regulatory Affairs position in Abbott Laboratories S.A. Spain handling products placing in the market, pricing and reimbursement of Nutritionals, Pharmaceuticals and Medical Devices.

Thanks to her broad Regulatory Affairs experience in the EU and broadly in EMEA countries, Estrella will play a key role in meeting the Company’s growth goals related to products tackling Iron Deficiency/Anemia and Gluten intolerance and sensitivity.

“I cannot think of anyone better than Estrella to join our team and contribute to the next stage of Nemysis development. Her undisputed competence and long-standing experience will provide new leads and perspective to the path to market of our pipeline products,” said Dr Maria Cristina Comelli, Director of R&D.

Estrella stated, “I am delighted to cooperate with Nemysis. I am impressed with the spirit of the Company which will allow bringing healthcare solutions worldwide, improving people’s lives. It is a great opportunity to deal with an excellent Team of an innovative company.”

Estrella has a Master’s in Pharmacy and Nutrition from the Complutense University of Madrid.

www.nemysisltd.com

About Nemysis:

Nemysis Ltd, a healthcare and pharmaceutical company, is focussed on nutritional and pharmaceutical solutions which can protect against some of the negative consequences of nutrient deficiency, nutrient intolerances and sensitivities, paying particular attention to the need to safeguard the human microbiome.

·         Nemysis’s novel nanoparticulate iron is the first natural ferritin mimic, which can correct human iron deficiency and anemia, without negatively impacting the gut microbiome. Safety and efficacy have been demonstrated in controlled-repeat-dose [clinical] trials.

·         Nemysis’s novel E40 endopeptidase is gastric, trypsin and chymotrypsin resistant. It has been shown to destroy all the immuno-stimulatory epitopes of gluten, quenching the exacerbated inflammatory response of primed, gluten-sensitive and hyper-responsive human T cells. It is, therefore, suitable for the enzymatic management of gluten intolerance and sensitivity.

·         Nemysis has three further products in its pipeline for use in Iron Deficiency/Anaemia, Gluten sensitivity and Celiac Disease

Read More  www.nemysisltd.com

Release date: May 15, 2020

Contact information

Danilo Casadei -Massari

Chairman of the Board

Nemysis Ltd

7 D’Olier Street

D02HF60 Dublin

Ireland

+35315313450

casadei-massari@nemysisltd.com

Nemysis Ltd Completes Second Round of Financing

Nemysis Limited, the Dublin-based pharmaceutical and healthcare Company focused on iron deficiency/anemia and gluten sensitivity has announced that it has completed a €2.65M capital raise.

Nemysis Limited, the Dublin-based pharmaceutical and healthcare Company focused on iron deficiency/anemia and gluten sensitivity, has announced that it has completed a €2.65M capital raise.

Currently a research-based Company, Nemysis has three high-potential products in its development pipeline, and it intends to use the net proceeds of the Placing to:

  • Expand clinical development of IHAT, its novel nanoparticulate iron, and prepare for potential commercialization in Europe.
  • To advance its other product pipeline and, in particular, the pre-industrialization process of E40, the Company’s novel endopeptidase for the enzymatic management of gluten intolerance and sensitivity.

Marco Cartolari, Executive Director, said: “We are very pleased with the progress we have made in the past year, and this financing will allow us to build on the momentum from all the positive development achievements on our innovative iron particulate product. Today’s oversubscribed private placement shows investors’ trust in Nemysis’ progress and potential.”

While furthering its preparatory activities for the worldwide commercialization of IHAT, the Company will now be able to accelerate its development plan for its other pipeline products in the gluten sensitivity area.

Cartolari’s remarks continued: “We appreciate the continued support of our existing shareholders and are glad to have added new investors. I’m delighted that such experienced, biotech and healthcare investors have decided to join our existing shareholders.

About Nemysis:

Nemysis Ltd, a healthcare and pharmaceutical company, is focussed on nutritional and pharmaceutical solutions that can protect against some of the negative consequences of nutrient deficiency, nutrient intolerances and sensitivities, paying particular attention to the need to safeguard the human microbiome.

· Nemysis’s novel nanoparticulate iron is the first natural ferritin mimic, which can correct human iron deficiency and anemia, without negatively impacting the gut microbiome. Safety and efficacy have been demonstrated in controlled-repeat-dose clinical trials.

· Nemysis’s novel E40 endopeptidase is gastric, trypsin and chymotrypsin resistant. It has been shown to destroy all the immuno-stimulatory epitopes of gluten, quenching the exacerbated inflammatory response of primed, gluten-sensitive and hyper-responsive human T cells. It is, therefore, suitable for the enzymatic management of gluten intolerance and sensitivity.

www.nemysisltd.com

​Nemysis, Food Supplements, Iron, Nano-Particulate Iron, Iron Deficiency/Anemia, IDA, Celiac Disease, CD, Non-Celiac Gluten Sensitivity, NCGS / NCWS, Pharmaceuticals, Biotech, IHAT, E40, Ireland Endopeptidase

Danilo Casadei Massari

Chairman of the Board

Nemysis Ltd

7 D’Olier Street

D02HF60 Dublin

Ireland

+35315313450

casadei-massari@nemysisltd.com

Seasoned Healthcare Executive, Guru Ramanathan, Joins Nemysis Ltd Board of Directors

Nemysis Limited today announced that it appointed Guru Ramanathan to its Board of Directors.

Guru Ramanathan, Senior Executive specialized in Global Healthcare innovation management and commercialization, brings with him over 30 years of leadership experience and knowledge worldwide, focused on customer-centric R&D, strategic business planning and pre- and post-marketing activities.

He served as Chief Innovation Officer at General Nutrition Corporation and, before that, he was Sr. Director of Scientific Affairs at Royal Numico (now Nutricia-Danone).

Thanks to his healthcare management experience, gained in the United States and South Asian emerging market, Guru will play a key role in meeting the company’s significant growth goals, as well as building on the firm’s impressive role in tackling iron deficiency/anemia and gluten intolerance.

“I cannot think of anyone better than Guru to join our Board into the next phase, so I am delighted that all Board Members and Shareholders agreed to appoint him as new Member of the Board of Directors. His ability to think strategically has already ensured him a pivotal role within the healthcare arena. His vision for how our new gluten intolerance products can be developed in the international market will support our next chapter of innovation and growth for Nemysis Ltd,” said Danilo Casadei Massari, Chairman of the Board of Directors.

Guru stated: “I am truly honoured to join the Directors of Nemysis. I am impressed with the entrepreneurial spirit that this company brings and look forward to a number of exciting developments in the months to come. It is a privilege to work with a group so committed to building a successful and innovative company.”

Guru achieved an MBA in General Management with special emphasis on global business practices, from Duke University, and a PhD in Healthcare Innovation Management from Tufts University.​

About Nemysis:

Nemysis Ltd, a healthcare and pharmaceutical company, is focussed on nutritional and pharmaceutical solutions that can protect against some of the negative consequences of nutrient deficiency, nutrient intolerances and sensitivities, paying particular attention to the need to safeguard the human microbiome.

· Nemysis’ novel nanoparticulate iron is the first natural ferritin mimic, which can correct human iron deficiency and anemia, without negatively impacting the gut microbiome. Safety and efficacy have been demonstrated in controlled repeat-dose clinical trials.

· Nemysis’ novel E40 endopeptidase is gastric, trypsin and chymotrypsin resistant. It has been shown to destroy all the immuno-stimulatory epitopes of gluten, quenching the exacerbated inflammatory response of primed, gluten-sensitive and hyper-responsive human T cells. It is, therefore, suitable for the enzymatic management of gluten intolerance and sensitivity.

www.nemysisltd.com

Contact information:

Danilo Casadei Massari

Chairman of the Board

Nemysis Ltd 7 D’Olier Street D02HF60, Dublin, Ireland +35315313450

casadei-massari@nemysisltd.com

NEWS LETTER SIGN UP

  • This field is for validation purposes and should be left unchanged.

Nutritional deficiency research for healthier living

Head Office
Suite 4.01 Ormond Building
31-36 Ormond Quay Upper
Arran Quay
Dublin 7
D07 F6DC
Ireland

© Nemysis Ltd 2024 | Web design by Genetic Digital Privacy Policy | Cookie Policy